1Institut für Pathologie der Ruhr-Universität Bochum an den BG-Kliniken Bergmannsheil. klaus.junker@rub.de
Neoadjuvant multimodality therapy for lung cancer shows tumor regression in resection specimens, which is a key prognostic factor. However, cytomorphological changes alone do not reliably predict therapy success.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Context:
Purpose:
Summary:
Impact: